Business Case

State Medicaid coverage assessment for a novel hemophilia drug

Our client, a top biopharma company, was looking to launch a novel hemophilia drug and wanted to understand the potential Medicaid coverage and reimbursement policies on a state-by-state basis. LSC was able to conduct detailed secondary and primary research to understand current state-level reimbursement and management, group states into key segments, define expected reimbursement and management for the novel asset. Through this assessment, client was able to deploy customized mitigation tactics in the influenceable state segments.